Guidelines for the use of AstraZeneca version of Saphnelo monoclonal antibody in the treatment of moderate to severe systemic lupus erythematosus
Saphnelo, as a targeted biological agent for the treatment of moderate to severe systemic lupus erythematosus, requires special attention to infection risk, medication for special populations, and monitoring of adverse reactions. The core precautions include management of active infections, prevention of allergic reactions, contraindications to vaccination, etc. The following items are explained in detail.
1. Infection risk control
(1) Active infection patients are prohibited from using it, and tuberculosis and chronic infections need to be screened before medication.
(2) During the treatment period, if a new infection occurs, medication should be suspended and restarted after it is under control.
(3) The risk of opportunistic infections increases, and it is necessary to monitor for signs of fungal, viral, and bacterial infections.
2 Allergies and infusion reactions
(1) The first infusion requires the provision of emergency equipment and monitoring of allergic symptoms such as difficulty breathing.
(2) Severe allergic reactions (such as angioedema) require permanent discontinuation of medication.
(3) Mild reactions can reduce infusion rate and be treated with antihistamines.
3. Medication for special populations
(1) Pregnancy period: Animal data shows embryotoxicity, human data is limited, and benefit risk needs to be evaluated.
(2) Breastfeeding period: Medications may be secreted with breast milk, and it is recommended to suspend breastfeeding during treatment.
(3) Elderly patients: higher risk of infection, need to strengthen monitoring and adjust dosage individualized.
4 vaccine contraindications
(1) Avoid receiving live vaccines (such as measles vaccine) as they may cause vaccine related infections.
(2) Inactivated vaccines can be administered, but the immune response may be weakened, and consultation with a physician is necessary.
(3) It is not recommended to receive live vaccines within 4 weeks before medication and 3 months after treatment.
5 Mental Health Monitoring
(1) May exacerbate depression or suicidal tendencies, evaluate the history of mental illness before medication.
(2) If emotional abnormalities occur during treatment, seek medical attention immediately and discontinue medication if necessary.
(3) Regular follow-up of psychological status, especially for patients with a history of mental illness.
Disclaimer：《Guidelines for the use of AstraZeneca version of Saphnelo monoclonal antibody in the treatment of moderate to severe systemic lupus erythematosus》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！